Microbot Medical to Demonstrate a Working Prototype of its Self-Cleaning Shunt at the Rodman & Renshaw Annual Global Investme...
05 Setembro 2019 - 5:05PM
At the upcoming Rodman & Renshaw Global Investment Conference,
Harel Gadot, CEO, President and Chairman of Microbot Medical Inc.
(Nasdaq: MBOT), will demonstrate a working prototype of the
Company’s Self-Cleaning Shunt (SCS™).
Mr. Gadot is scheduled to present on Tuesday,
September 10, 2019, at 12:05 pm (ET), at the Lotte New York Palace
in New York City. A live webcast and subsequent archived replay of
the Company’s presentation may be accessed via the ‘Investors’
section, under ‘Presentation + Resources’ of the Company’s website
at www.microbotmedical.com.
About Microbot Medical Inc.
Microbot™, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
technological platforms, ViRobTM, TipCATTM and CardioSertTM, are
comprised of three highly advanced technologies, from which the
Company is currently developing its first product candidate: The
Self-Cleaning Shunt, or SCSTM, for the treatment of hydrocephalus
and Normal Pressure Hydrocephalus, or NPH. The Company also is
focused on the development of a Multi Generation Pipeline Portfolio
(MGPP) utilizing all technologies. Further information about
Microbot Medical is available at
http://www.microbotmedical.com.
The ViRobTM technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to navigate and
crawl in different spaces within the human body, including blood
vessels, the digestive tract and the respiratory system. Its unique
structure gives it the ability to move in tight spaces and curved
passages as well as the ability to remain within the human body for
prolonged time. To learn more about ViRobTM please visit
http://www.microbotmedical.com/technology/virob/.
TipCATTM is a transformational self-propelled,
flexible, and semi-disposable locomotive device providing see &
treat capabilities within tubular lumens in the human body such as
the colon, blood vessels, and the urinary tract. Its
locomotion mechanism is perfectly suitable to navigate and crawl
through natural & artificial tubular lumens, applying the
minimal necessary pressure to achieve the adequate friction
required for gentle, fast, and safe advancement within the human
body. To learn more about TipCATTM, visit
http://www.microbotmedical.com/technology/tipcat/.
CardioSertTM technology contemplates a unique
combination of a guidewire and microcatheter, technologies that are
broadly used for endoluminal surgery. The CardioSertTM technology
features unique steering and stiffness control capabilities, and it
was originally developed to support interventional cardiologists in
crossing the most complex lesions called chronic total occlusion
(CTO) during percutaneous coronary intervention (PCI) procedures
and has the potential to be used in other spaces and applications,
such as peripheral intervention, neurosurgery and urology.
CardioSertTM was part of a technological incubator supported by the
Israel Innovation Authorities (formerly known as the Office of the
Chief Scientist, or OCS), and its device has successfully completed
pre-clinical testing.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, the
outcome of its studies to evaluate the SCS and other existing and
future technologies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially
from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many
uncertainties that affect the businesses of Microbot Medical Inc.
particularly those mentioned in the cautionary statements found in
Microbot Medical Inc.’s filings with the Securities and Exchange
Commission. Microbot Medical disclaims any intent or obligation to
update these forward-looking statements.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024